Birmingham leads the way in delivery of a new advanced therapy in uveal melanoma
BHP founder-member University Hospitals Birmingham is the first site in the UK to treat a uveal melanoma patient with the new therapy Tebentafusp outside a clinical trial. Uveal melanoma is a rare …
Genetic diagnosis leads the way in childhood eye cancer treatment
Experts from BHP member Birmingham Women’s and Children’s NHS Foundation Trust have transformed the treatment of children’s eye cancer with pioneering new research.
Dr Trevor Cole and Dr Amy Ger…
SPIRIT-PRO extension: guidelines for inclusion of patient-reported outcomes in protocols of clinical trials
Patient Reported Outcomes (PROs) can provide valuable evidence on the impact of disease and treatment on patients’ symptoms, function and quality of life. High-quality PRO data from trials can info…
Scientists discover new pathway that prevents bowel cancer treatment from working
Leading scientists at BHP founder-member the University of Birmingham have discovered a previously unknown pathway that prevents specific drugs from working in patients with bowel cancer.
The rese…
High-profile appointee to lead Birmingham’s Precision Health Technologies Accelerator
The University of Birmingham has announced the appointment of an experienced academic and industrial pharmaceutical professional to the position of Managing Director of its new Precision Health Tec…
AI to improve treatments for people with multiple long-term conditions
The NIHR has awarded £2.5 million for new artificial intelligence (AI) research led by the University of Birmingham. The study will use AI to produce computer programmes and tools to help doctors i…